Fredun Pharmaceuticals bulk deals, insider trading and stake changes
NSE: FREDUNBSE: 539730Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,391.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,313 Cr1,474th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 8.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 18.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.80
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 52,74940.2% delivered
Promoter and insider buying and selling
Trades made since 23 Oct 2025.Fredun Pharmaceuticals promoter holding
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 2 off-market moves
Fredun Pharmaceuticals insider trading
All 10 disclosures on record.Insider trading, all companies
Jul 2026
- BonusEach share became 3 on 16 Jul 2026. The lines below are on the share count before it.
Apr 2026
- Daulat Medhora₹5.00 Cr40,000 sharesReceived · Promoter & Director · 9 Apr 2026 · disclosed 10 Apr · Conversion of security · stake 25.78% before, 26.32% after
Mar 2026
- FREDUN MEDHORA₹13 Cr1,06,668 sharesReceived · Promoter and Director · 25 Mar 2026 · disclosed 26 Mar · Conversion of security · held 1,79,672 before, holds 2,86,340 after, stake 5.23% after
Aug 2023
- DAULAT MEDHORA₹1.80 Cr18,068 sharesReceived · Promoter and Director · 23 Aug 2023 · disclosed 25 Aug · Allotment · stake 30.11% before, 30.38% after
Oct 2022
- Fredun Medhora₹1.90 Cr19,072 unitsReceived · Promoter and Director · 15 Oct 2022 · Warrant · disclosed 17 Oct · Allotment · held none before, holds 19,072 after
- Daulat Medhora₹1.80 Cr18,068 unitsReceived · Promoter and Director · 15 Oct 2022 · Warrant · disclosed 17 Oct · Allotment · held none before, holds 18,068 after
Sep 2022
- Fredun Medhora₹1.90 Cr19,072 sharesReceived · Promoter and Director · 22 Sep 2022 · Allotment · held 1,60,100 before, holds 1,79,172 after
Earlier, Nov 2021 to Nov 2021Hide earlier
Nov 2021
- Nariman Medhora₹6.10 Cr1,44,515 sharesReceived · Promoter and Director · 23 Nov 2021 · Allotment · held 5,75,300 before, holds 7,19,815 after
- Daulat Medhora₹2.20 Cr52,120 sharesReceived · Promoter and Director · 23 Nov 2021 · Allotment · held 13,40,710 before, holds 13,92,830 after
- Nariman Medhora₹6.10 Cr1,44,515 unitsReceived · Promoter and Director · 17 Nov 2021 · Warrant · disclosed 18 Nov · Allotment · held none before, holds 1,44,515 after
- Daulat Medhora₹2.20 Cr52,210 unitsReceived · Promoter and Director · 17 Nov 2021 · Warrant · disclosed 18 Nov · Allotment · held none before, holds 52,210 after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Fredun Pharmaceuticals stake sales and purchases
All 2 disclosures on record.
Jul 2026
- BonusEach share became 3 on 16 Jul 2026. The lines below are on the share count before it.
Apr 2026
- AcquiredFredun Nariman Medhora & Others · promoter0.73% of the company40,000 sharesholds 44.57% after9 Apr 2026 · filed under the 2% rule · Conversion of warrants
Nov 2021
- AcquiredNikhil Vora2.52% of the company1,06,846 sharesholds 8.03% after17 Nov 2021 · filed under the 2% rule · Preferential allotment
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Fredun Pharmaceuticals bulk deals
None in the last 12 months, since 23 Oct 2025.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Tuesday 14 Sep 20212 firms · ₹0 bought · ₹2.11 Cr soldNet sold ₹2.11 Cr
- SoldASHOK JHINGANSold 24,000 at ₹443.070.60% of the company₹1.06 Cr
- SoldANAND JHINGANSold 24,758 at ₹422.480.62% of the company₹1.05 Cr
Wednesday 1 Jul 20203 firms · ₹3.17 Cr bought · ₹3.15 Cr soldNet bought ₹0.02 Cr
- Both waysZAHEER .Bought 1,12,025 at ₹186.01Sold 1,12,025 at ₹183.282.81% of the companyNet nil₹2.08 Cr bought
- Both waysSURINDER GURMUKH DHAULBought 24,881 at ₹183.48Sold 24,881 at ₹186.190.62% of the companyNet nil₹0.46 Cr bought
- Both waysKAMAL KUMAR JALAN SEC. PVT. LTDBought 33,872 at ₹184.83Sold 33,697 at ₹187.300.85% of the companyNet +175 shares₹0.63 Cr bought
Monday 15 Jan 20181 firm · ₹0 bought · ₹0.22 Cr soldNet sold ₹0.22 Cr
- SoldMADHUBALA PARESH TRIVEDISold 15,400 at ₹142.700.53% of the company₹0.22 Cr
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 9 deals on record since listing on 21 Mar 2016.